- Home
- Pathology Industry
- Dendreon Market and Forecasts, June 2013
Industries
- Pathology (14)
- Drug and Medication (7)
- Biological Therapy (6)
- Blood Supply, Tissue Banking and Transplantation (1)
- Diagnostics (1)
-
- Drug Discovery and Development (1)
- Energy & Environment (1)
- Healthcare (1)
- In Vitro Diagnostic (1)
- Investment Banking (1)
- Oil and Gas Energy (1)
- Pharmaceutical (1)
Top countries
Publication dates
All regions
data types
- All
- Company Data (370)
- Industry Data
- Country Data (16)
Dendreon Market and Forecasts, June 2013
You might be interested in: cell therapy, vaccine, ovarian cancer, more »
industry reports
country reports
» Download Public Reports
1-10 of 36 reports for Dendreon
Blood Supply Sector Brief
- Industry report
- October 2011
- 2 pages
... With the help of blood centers, after the first year of fda approval. As provenge continues to become available for more patients, dendreon S manufacturing capability is expected to increase. Medicare ...
- Industries: Blood Supply, Tissue Banking and Transplantation
Drug and Medication Market in The United States
- Industry report
- November 2011
- 6 pages
- by Corporation
... Throughout the biotech sector as investors dumped shares of firms nearing the launch of other highly anticipated drugs. With its stock price falling 25% since dendreon's announcement, rare ...
- Industries: Drug and Medication
- Countries: United States
Pharmaceutical Business Brief
- Industry report
- February 2013
- 9 pages
... That would mirror the experience with dendreon S provenge. Xtandi trailing zytiga in awareness, more equal in terms of physicians Perception. Not surprisingly, community urologists report significantly ...
- Industries: Pathology
Pharmaceutical Market in The United States
- Industry report
- July 2011
- 11 pages
... That management characterized as productive. Source: goldman sachs/flynn, july 6, 2011 oncology indication: thyroid keyword: clinical trials/pipeline back to front page dendreon: 2nd provenge survey ...
- Industries: Pathology
- Countries: United States
U.S. Biological Therapy Business
- Industry report
- April 2012
- 20 pages
... For products from an individual donor Cv of % mnc averaged 7.7% For all products 16 17 external quality indicators dendreon supplier scorecard 18 summary Collecting blood ...
- Industries: Biological Therapy
- Countries: United States
Cell Therapy Business in The United States, Belgium and The United Kingdom
- Industry report
- December 2011
- 4 pages
... And cso, intercytex, uk Dr wilfried dalemans, chief technical officer, tigenix, belgium Dr myles marcus, vp, supply chain, dendreon, usa Dr deborah ladenheim, vp regulatory affairs, athersys inc, usa ...
- Industries: Biological Therapy
- Countries: United States, Belgium, United Kingdom
Drug and Medication Industry in The United States and Japan
- Industry report
- May 2011
- 9 pages
... Strategy/financials back to front page dendreon: continued execution should position provenge well for near- and long-term; likely to meet, if not exceed, 2011 sales guidance of $350-$400m in the next month, we expect ...
- Industries: Drug and Medication
- Countries: United States, Japan
Pharmaceutical Sector in Australia
- Industry report
- February 2012
- 27 pages
- by Corporation
... And toxicity profile Research into cancer immunotherapy has led to recent regulatory approval success: dendreon S provenge approval in 2010 (fda) Bristol-myers squibb S yervoy approval in 2012 (fda ...
U.S. Healthcare Industry Brief
- Industry report
- April 2012
- 50 pages
... Medicare advisers want more data Cms final ruling on whether to pay for provenge in march 2011 Medicare panel backs prostate drug. New york times. 11/17/10. Us panel backs dendreon S provenge ...
- Industries: Healthcare
- Countries: United States
Pharmaceutical Market in Australia
- Industry report
- February 2012
- 27 pages
... And toxicity profile Research into cancer immunotherapy has led to recent regulatory approval success: dendreon S provenge approval in 2010 (fda) Bristol-myers squibb S yervoy approval in 2012 (fda ...
Reportlinker.com © Copyright 2013. All rights reserved.
